64 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case … as would not have or reasonably be expected to result in a Material Adverse Effect.
(m) Environmental Laws. The Company and its Subsidiaries (i
424B4
PCSA
Processa Pharmaceuticals Inc
29 Jan 24
Prospectus supplement with pricing info
4:15pm
compliance issues, environmental, intellectual property and title matters and compliance with various laws such as the Foreign Corrupt Practices Act
8-K
EX-10.1
bmesirrmsv asj
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
ybk9hdlx42lgc pt3
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
D
qshpc
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
8-K
EX-10.1
mse3z8j9cdr
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
yrmlkzvr7c6rggrn0zq2
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
4nl26lc459tpebsnb
5 Oct 20
Prospectus supplement with pricing info
4:16pm